Lead Product(s) : SJ-600
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : SillaJen, Inc
Deal Size : Undisclosed
Deal Type : Partnership
ReiThera Partners with SillaJen to Develop & Produce the SJ-600 Series for Clinical Trials
Details : Through the partnership, ReiThera will leverage its expertise to conduct advanced development & production of the SJ-600 series, transforming it into a clinical-ready drug capable of entering trials.
Product Name : SJ-600
Product Type : Vaccine
Upfront Cash : Undisclosed
January 24, 2025
Lead Product(s) : SJ-600
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : SillaJen, Inc
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AM E3-SG3249
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
IRBM to Present Efficacy of Preclinical Agents Against Brain Tumors at AACR
Details : AM E3-SG3249, is a CRLF2/TLSP inhibitor, a preclinical candidate which is being investigated for the treatment of philadelphia chromosome-like acute lymphoblastic leukemia.
Product Name : AM E3-SG3249
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
April 04, 2024
Lead Product(s) : AM E3-SG3249
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RR001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rigenerand Receives Regulatory Approval for Gene Therapy Production
Details : This authorization enables Rigenerand to manufacturer its own autologous gene therapy medicinal product (RR001) for the treatment of pancreatic cancer. It also authorizes the company to start its phase I first-in-man clinical trial of RR001.
Product Name : RR001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : RR001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable